Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

Kleiter, Ingo and Hellwig, Kerstin and Berthele, Achim and Kuempfel, Tania and Linker, Ralf A. and Hartung, Hans-Peter and Paul, Friedemann and Aktas, Orhan (2012) Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. ARCHIVES OF NEUROLOGY, 69 (2). pp. 239-245. ISSN 0003-9942, 1538-3687

Full text not available from this repository. (Request a copy)

Abstract

Objective: To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). Design: Retrospective case series. Setting: Neurology departments at tertiary referral centers in Germany. Patients: Patients with NMO who tested positive for antibodies to aquaporin 4. Intervention: Treatment with natalizumab. Main Outcome Measures: Relapses and accumulation of disability. Results: We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated with natalizumab before diagnosis of NMO was established. Natalizumab was given as escalation therapy after failure of first- or second-line immunomodulatory therapies for MS. During natalizumab therapy (median duration, 8 infusions; range, 2-11 infusions), all 5 patients displayed persisting disease activity; a total of 9 relapses occurred (median duration to relapse, 120 days; range, 45-230 days) after the start of treatment. Four patients had an accumulation of disability and 1 patient died 2 months after cessation of natalizumab treatment. Conclusions: Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy.

Item Type: Article
Uncontrolled Keywords: MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; BIOMARKER SIGNATURE; DIAGNOSIS; TAU; EPSILON-4; PATHOLOGY; ALLELE; TRIAL;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Neurologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 May 2020 04:45
Last Modified: 22 May 2020 04:45
URI: https://pred.uni-regensburg.de/id/eprint/19305

Actions (login required)

View Item View Item